Sun Pharma receives DCGI approval for Molxvir in India
The product is expected to be available in a week’s time
The product is expected to be available in a week’s time
DCGI approved the drug based on the review of clinical data
The drug will be marketed under the brand name Molnaflu
Flattish volume growth and subdued new launches were key factors for last month
Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services
He has over 22 years of experience in pharmaceutical sales & business development
2022 is going to be the year of opportunities and innovations from the medical industry in India
Over the next few years, Philips aims to double the number of its active cath labs in India with a special focus on improving accessibility to quality cardiac and neurovascular care in tier 2 and tier 3 cities
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Subscribe To Our Newsletter & Stay Updated